AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06174688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular Injections
Study NCT06443177 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vectris trial leads and stimulation
Description: The electrode is placed into the epidural space using standard epidural placement techniques with paramedian approach. The initial electrode settings have been adopted from prior studies. Should any significant discomfort be elicited from the stimulation, first the amplitude will be decreased to an acceptable level. If an acceptable level of stimulation is unable to be found, the stimulation will be discontinued.
Study NCT06443177 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: No electrode is placed.
Study NCT04740281 — intervention group
Intervention type: BEHAVIORAL
Intervention: Footwear
Description: Assessment of footwear
Study NCT05120973 — intervention group
Intervention type: PROCEDURE
Intervention: multispectral imaging
Description: Sentinel node biopsy with Indocyanine Green -Technetium - Nanocolloid + fluorescein
Study NCT05120973 — intervention group
Intervention type: PROCEDURE
Intervention: fluorescence for lymphatic mapping
Description: Indocyanine green injected in abdominal wall
Study NCT06241638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B12 0.5 MG/ACTUAT
Description: The investigators measured the blood levels of Vitamin B12 and HbA1c as well as the BMI in two study groups; The Experimental group: Vitamin B12 and Dapagliflozin group and Active Comparator group: Dapagliflozin group.~The Dapagliflozin group received only Dapagliflozin 10 mg/daily orally for twelve months, whereas, the Vitamin B12 and Dapagliflozin group received Vit. B12 supplements methylcobalamin 500 µg once daily orally with the anti-diabetic therapy Dapagliflozin 10 mg/daily orally for twelve months.
Study NCT06241638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: The investigators measured the blood levels of Vitamin B12 and HbA1c as well as the BMI in two study groups; The Experimental group: Vitamin B12 and Dapagliflozin group and Active Comparator group: Dapagliflozin group.~The Dapagliflozin group received only Dapagliflozin 10 mg/daily orally for twelve months, whereas, the Vitamin B12 and Dapagliflozin group received Vit. B12 supplements methylcobalamin 500 µg once daily orally with the anti-diabetic therapy Dapagliflozin 10 mg/daily orally for twelve months.
Study NCT06241638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg Tab
Description: The investigators measured the blood levels of Vitamin B12 and HbA1c as well as the BMI in two study groups; The Experimental group: Vitamin B12 and Dapagliflozin group and Active Comparator group: Dapagliflozin group.~The Dapagliflozin group received only Dapagliflozin 10 mg/daily orally for twelve months, whereas, the Vitamin B12 and Dapagliflozin group received Vit. B12 supplements methylcobalamin 500 µg once daily orally with the anti-diabetic therapy Dapagliflozin 10 mg/daily orally for twelve months.
Study NCT06521515 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Ultrasound Morphology Patterns
Description: Two blinded investigators conducted daily lung ultrasound examinations. Each lung was scanned in six regions, categorizing ultrasound findings into four aeration patterns: normal (N-score 0), moderate (B1-lines score 1), severe (B2-lines score 2), and consolidation (C-score 3). The global LUS score ranged from 0 to 36. Patients were grouped into TLP if they exhibited a tissue-like pattern in any region or DBP if they displayed diffuse B-lines and shred signs in most regions. Localized TLPs indicated concentrated areas of non-aeration.
Study NCT05887544 — intervention group
Intervention type: OTHER
Intervention: Exposure: Plant-based diet pattern
Description: From dietary records average intake across food groups will be calculated and a plant-based diet index score will be generated to group participants.
Study NCT05887544 — intervention group
Intervention type: OTHER
Intervention: Intervention: Fermented dairy products
Description: 1000g of the product to be consumed 1-2 days prior to spot urine sample.
Study NCT05887544 — intervention group
Intervention type: OTHER
Intervention: Exposure: individual foods and food groups
Description: From the dietary records, average intake of specific foods or food groups will be calcualted.
Study NCT05763186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sampling
Description: Comparison of the results of the biological examinations obtained on the 6 tubes collected on the PiccLine with the results of the biological examinations obtained on the peripheral sample.
Study NCT05763186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sampling and rinsing
Description: Comparison of the results of the biological examinations obtained on the 6 tubes collected on the PiccLine with the results of the biological examinations obtained on the peripheral sample.
Study NCT05853198 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ctDNA analysis
Description: ctDNA amount and mutations analysis
Study NCT05015127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM9161 680 mg qw by q2w from week 13
Description: HBM9161 680 mg qw by q2w from week 13
Study NCT05015127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT05015127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM9161 680 mg qw by q2w from week 7
Description: HBM9161 680 mg qw by q2w from week 7
Study NCT05015127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo qw by HBM9161 680mg qw from week 12
Study NCT05522101 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mini-sized MCE
Description: AKES-31SW capsule endoscopy（Mini-sized MCE), its diameter is 9.5mm, length is 24.5mm, weight is 3.0g, shooting frequency is 0.5-6fps, image resolution is 480\*480, working time is not less than 8 hours. Mini-sized MCE is 0.6 times of traditional MCE in volume and weight, which is the smallest capsule in clinical application
Study NCT05522101 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Normal-sized MCE
Description: Pillcam SB 3 capsule endoscopy（Normal-sized MCE), its diameter is 11.4mm, length is 26.2mm, weight is 3.0g, shooting frequency is 2-6fps, image resolution is 340\*340, working time is not less than 8 hours.
Study NCT05843981 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement TS III
Description: Implant placement in subjects who have lost at least two teeth and need a prosthetic implant rehabilitation with TSIII Implant. . After osseointegration, dental implants will receive definitive prosthesis.
Study NCT05843981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant placement ks
Description: Implant placement in subjects who have lost at least two teeth and need a prosthetic implant rehabilitation with KS Implant. After osseointegration, dental implants will receive definitive prosthesis.
Study NCT06224101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation-based training
Description: simulation training consists of practicing diagnostic coronary angiography with 3D printed simulator-SimulHeart.
Study NCT04267367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietitian-led dietary approach to management of diabetes
Description: In the intervention phase, the educational and diet plan package will be developed. All the intervention packages will be approved by a multi-disciplinary expert team comprising an endocrinologist and dietitian prior to the intervention. Patients in the usual care arm will receive routine care as to how he/she is practicing in their daily life. Routine care includes general knowledge on diabetes disease process, blood glucose monitoring, a healthy lifestyle, preventing treating diabetes complications and developing personalized strategies for the decision-making process\[27\]. The intervention package will include mainly two-phase, nutritional counseling emphasis on lifestyle modification of diabetes patients and individual basis diet plan for each T2DM patients for intervention arm. The nutrition education and counseling and individual diet plan will be applied by trained dietitians.
Study NCT01970449 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA Nat-B env vaccine
Description: The DNA Nat-B env vaccine will be administered as a 4-mg dose injection intramuscularly (IM) by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
Study NCT01970449 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC Nat-B env vaccine
Description: NVYAC Nat-B env vaccine will be administered as a 3 × 10\^7 plaque forming units (pfu) dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
Study NCT01970449 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA CON-S env vaccine
Description: The DNA CON-S env vaccine will be administered as a 4-mg dose injection IM by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
Study NCT01970449 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC CON-S env vaccine
Description: NVYAC CON-S env vaccine will be administered as a 3 × 10\^7 pfu dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
Study NCT01970449 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA Mosaic env vaccine
Description: The DNA Mosaic env vaccine will be administered as a 4-mg dose injection IM by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
Study NCT01970449 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC Mosaic env vaccine
Description: NVYAC Mosaic env vaccine will be administered as a 3 × 10\^7 pfu dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
Study NCT01970449 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for both DNA and NYVAC vaccines will be administered in the deltoid muscle of the non-dominant arm (unless medically contraindicated) as sodium chloride for injection, 0.9%.
Study NCT01970449 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biojector 2000® Needle-Free Injection Management System™ (Biojector 2000®)
Description: All three DNA env vaccines will be administered IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated) using the Biojector 2000® device.
Study NCT05059821 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide cancer vaccine
Description: Vaccine content are personalized peptides vaccine separated from each patients own tumor cells, autologous heat shock protein 70 separated from tumor cells and autologous activated monocytes that administered subcutaneously monthly for six months
Study NCT04960930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX101
Description: topically once daily
Study NCT04960930 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FMX101
Description: topically once daily
Study NCT04998539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheelchair forward direction
Description: Participants will move the wheelchair over 5 meters of a soft surface (gym mats) in the forward direction. Participants will push the wheelchair when moving forward.
Study NCT01737749 — intervention group
Intervention type: DEVICE
Intervention: Neurokeeper stroke detector
Description: Electrophisoloigcal monitoring
Study NCT06194760 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vitrectomy with ILM peeling
Description: Vitrectomy with traditional internal limiting membrane (ILM) peeling technique is regarded as the gold standard treatment for MH; it works by completely relieving of the traction of the macula and increasing the flexibility of the retina
Study NCT03536052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Heart Guided Ablation
Description: If a good quality cardiac MRI is obtained and a virtual heart model with the ablation targets is generated, the operating physician will merge the virtual heart lesion map to the invasive electroanatomical navigation system. After the patient has been catheterized, an attempt should be made to induce VT. The physician should then navigate the catheter to each of the ablation targets specified, and place a lesion as per his or her training and experience, confirming when done that the lesion marker in the mapping system coincides with the target. This will be done for each lesion.
Study NCT05317338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based exercise training during hospitalization
Description: Multicomponent exercises for 5-7 days with acutely hospitalized older.
Study NCT05130476 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Near-infrared-induced autofluorescence and indocyanine green near-infrared angiography
Description: During thyroid surgery, near-infrared-induced autofluorescence is used for the identification of the parathyroid glands, combined with indocyanine green near-infrared angiography for identification of the parathyroid feeding vessels.
Study NCT06306534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory Nerve Acute (ANA) Electrode Array
Description: To measure eABRs when stimulating the human auditory nerve
Study NCT05154461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alginate
Description: BHB covered in alginate will be realised in stomach-duodenum
Study NCT05154461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea-protein
Description: BHB covered in pea-protein will be released in ileum-colon
Study NCT05659212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Patients will receive IV dexmedetomidine 0.5 μg /kg diluted up to 10 ml with normal saline infused over 10 min before induction of anesthesia, and 10 ml of normal saline immediately before induction of anesthesia.
Study NCT05659212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate
Description: Patients will receive IV magnesium sulphate 50 mg/kg diluted up to 10 ml with normal saline infused slowly over 10 min before induction of anesthesia, and 10 ml of normal saline immediately before induction of anesthesia.
Study NCT05328466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The engineer-built system, video-game based Kinect sensor
Description: The games were developed by the researcher team.
Study NCT05659212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Patients will receive IV lidocaine 1.5 mg/ kg diluted up to 10 ml with normal saline immediately before induction of anesthesia and 10 ml of normal saline infused over 10 min before induction of anesthesia.
Study NCT06209281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lower dose atropine sulfate eye drops
Description: Administer to eyes
Study NCT06209281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose atropine sulfate eye drops
Description: Administer to eyes
Study NCT06209281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administer to eyes
Study NCT06548945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR18
Description: 5 mg-maximum tolerated dose (MTD), single dose
Study NCT06548945 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered the same volume as GZR18
Study NCT04998539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheelchair backward direction
Description: Participants will move the wheelchair over 5 meters of a soft surface (gym mats) in the backward direction. Participants will pull the wheelchair when moving backwards.
Study NCT04998539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upright technique
Description: Participants will move the wheelchair across the 5 m soft surface using the upright technique. The upright technique involves the wheelchair being moved with all 4 wheels on the ground.
Study NCT04998539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheelie technique
Description: Participants will move the wheelchair across the 5 m soft surface using the wheelie technique. The wheelie technique involves the wheelchair being tipped backward and balanced on the rear wheels. Participant wheelchair occupants will always be upright when being moved using the wheelie technique.
Study NCT04998539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheelchair occupant upright body position
Description: The participant occupying the wheelchair (wheelchair occupant) will be seated with a body position that is upright (back is leaning against the wheelchair back rest and arms on wheelchair arm rests) while the wheelchair is being moved.
Study NCT05868928 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging (MRI)
Description: Pre-and post-contrast enhanced T1-weighted image, T2-weighted image, fluid-attenuated inversion recovery image
Study NCT05868928 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diffusion-weighted MRI
Description: Diffusion-weighted MRI
Study NCT05868928 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Arterial spin labeling (ASL)
Description: Cerebral blood flow imaging parameter
Study NCT05868928 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamic susceptibility contrast-MRI (DSC-MRI)
Description: Cerebral blood volume and vessel architectural imaging parameters
Study NCT05452369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rhomboid intercostal plane block
Description: - 30 mL bupivacaine 0.25% will injected ultrasound-guided in rhomboid intercostal fascial plane .
Study NCT06463145 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vanizem
Description: Aframomum melegueta seed extract standardized to 10% of total Vanilloid and at least 1.5% of 6-paradol
Study NCT06463145 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Food grade Maltodextrin 12
Study NCT05216796 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet Intervention
Description: Meal will be prepared and delivered by SNAP Kitchen, which has 7 locations in Austin and offers 20+ options for low-carbohydrate and low-calorie meals, each meal available in different sizes varying in energy intake. Meals will be entered into the Nutrition Data System for Research (NDS-R) software to confirm low-calorie profile. Meals will be delivered to participants' homes twice a week.
Study NCT05216796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet Intervention
Description: Meal will be prepared and delivered by SNAP Kitchen, which has 7 locations in Austin and offers 20+ options for low-carbohydrate and low-calorie meals, each meal available in different sizes varying in energy intake. Meals will be entered into the Nutrition Data System for Research (NDS-R) software to confirm low-calorie profile. Meals will be delivered to participants' homes twice a week.
Study NCT04693741 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: secondary alveolar bone graft
Description: Under general anesthesia, the soft tissue in the gingiva surrounding the alveolar cleft will be injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. At the alveolar cleft site, gingival sulcus incisions will be made on both sides of the cleft. The tissue will then elevated beneath the periosteum. The mucosa of the nasal floor and the oral mucosa will be dissected. Next, the bone particles will be implanted into the bone defect.~Then, The cleft site will be closed without tension by the advancement of the gingival flaps.
Study NCT04693741 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Harvesting of the autogenous bone graft
Description: Under general anaesthesia ,the soft tissue in the superior iliac crest will injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. The cancellous bone will harvested with an osteotome and then cut into small bone granules.
Study NCT04693741 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Preparation of PRP
Description: 10 ml of blood will be collected in vacuum tubes without anticoagulants which are then immediately centrifuged at a rate of 3000 rpm for 10 min. After centrifugation, the resultant product consists of three layers. The topmost layer consisting of acellular PPP (platelet poor plasma), PRF clot in the middle and RBCs at the bottom of the test tube. The attached red blood cells scraped off from it and discarded. The discarded PRF is then mixed with xenograft and placed inside the alveolar defect.
Study NCT05782894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: 0\~2.0mg/kg/h
Study NCT05782894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 0.3\~4.0mg/kg/h
Study NCT05782894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: 1.5\~12μg/kg/h
Study NCT05782894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: 1.5\~12μg/kg/h
Study NCT04726150 — intervention group
Intervention type: OTHER
Intervention: ILR implantation
Description: If LGE is present on CMR, ILR implantation will be proposed
Study NCT06009237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-903
Description: Tablet; oral
Study NCT06009237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-903
Description: Tablet; oral